Short answer
Aura Biosciences, Inc. (AURA) filed an 8-K current report with the SEC on May 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Quarterly results cover the period ended March 31, 2026.
Aura Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly results cover the period ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains Aura Biosciences’ financial results and related disclosures
Item 8.01 · Other Events
- Forward-looking statement disclaimer covering clinical development, regulatory approval, trial enrollment, and data timing risks
- Phase 3 Special Protocol agreement with the FDA does not eliminate risk of regulatory disagreement
- Cash sufficiency risk for foreseeable and unforeseeable operating expenses and capital expenditures
- Investors should rely on current SEC filings’ risk factors rather than projections in this disclosure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aura Biosciences, Inc. 8-K filings
Get the next AURA 8-K as it lands
Follow AURA for push alerts, or ask the research agent what this filing means.